Skip to main content
Solid Tumor Thoracic Cancer

Thoracic Cancer

Development of bronchopleural fistula after neoadjuvant immunochemotherapy

Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.

Severe megaloblastic anemia related to erlotinib

Open Access NSCLC Case Study

The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.

Trial reassures on SABR use in NSCLC patients with ILD

14-03-2024 NSCLC News

Phase 2 data point to a favorable benefit–risk balance of stereotactic ablative radiotherapy in many patients with early-stage NSCLC and interstitial lung disease.

Managing malignant pleural effusion

Open Access Pleural Effusion Review

Great progress has been made in developing strategies to manage malignant pleural effusion, but these still primarily focus on optimal drainage. More research is needed to advance understanding of mechanistic drivers and develop targeted therapies.

Lung cancer in a transplanted lung

Open Access Lung Cancer Case Study

Successful surgical resection of lung cancer arising in a transplanted lung, using venovenous extracorporeal membrane oxygenation to overcome the challenge of single-lung ventilation during the procedure. 

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
NSCLC Podcast

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares

Current Reviews

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments

NSCLC Review Article

Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS mutant NSCLC is a heterogenous group of diseases, different from other …

Immune Checkpoint Inhibitors in Geriatric Oncology

Cancer is widely considered a disease of aging. The care of older adults with cancer is complicated by factors such as frailty, multiple comorbidities, and age-related organ dysfunction [ 1 ]. These issues pose specific challenges to optimal …

Recent advances in lung cancer research: unravelling the future of treatment

Lung Cancer Review Article

Lung cancer, a multifaceted disease, demands tailored therapeutic approaches due to its diverse subtypes and stages. This comprehensive review explores the intricate landscape of lung cancer research, delving into recent breakthroughs and their …

N1-positive non-small cell lung cancer: surgeons’ perspective before undertaking a major resection

NSCLC Mini Review Article

Among various reasons for a rise in surgical referrals for locally advanced non-small cell lung cancer, few are improved clinical-pathological staging, better understanding of oncological driver mutation, and aggressive neoadjuvant treatment …

Biomarkers Podcast

Episode 5: Next-generation sequencing

Emerging biomarkers in thyroid and non-small cell lung cancers

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.

Prof. Andrew Beggs
Developed by: Springer Healthcare

Case Studies

Development of bronchopleural fistula after neoadjuvant immunochemotherapy

Bronchopleural fistula is a rare but potentially fatal complication that can occur after surgery in patients receiving neoadjuvant immunochemotherapy for stage III NSCLC.

Severe megaloblastic anemia related to erlotinib

Open Access NSCLC Case Study

The first case of severe megaloblastic anemia in a patient treated with erlotinib for advanced NSCLC. It highlights the need for close clinical and blood monitoring in people receiving long-term TKI therapy.

Rare example of a metastatic brain tumor infiltrating a meningioma

Open Access Meningioma Case Study

Tumor-to-tumor metastasis is the most common extracranial cancer metastasis to existing brain tumors, whereas a rare form is metastasis infiltrating tumor. In this case, a lung cancer tumor metastasized adjacent to and partially infiltrated an existing meningioma.

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

eLearning | Interviews | Digital Treatment Map (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Digital Treatment Map (Link opens in a new window)

Practical, expert-led digital map designed to guide treatment of ALK- and ROS1-mutation positive NSCLC.

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME

Related topics

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Further Reading

Development and evaluation of two open-source nnU-Net models for automatic segmentation of lung tumors on PET and CT images with and without respiratory motion compensation

Open Access Positron Emission Tomography Oncology

In lung cancer, the ability of Positron Emission Tomography (PET) with [18F]fluoro-2-deoxy-D-glucose (FDG) to exploit the biochemical differences between normal and neoplastic tissue [ 1 ] has been proven to be a valuable tool for tumor detection [ …2

Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields

Open Access NSCLC INTERVENTIONAL PULMONOLOGY

Lung cancer represents one of the leading causes of cancer-related deaths, but substantial advances have been made in enhancing the ways in which lung cancers are histologically identified and molecularly profiled. As a result, several targeted …

Clinical outcomes of left upper segmentectomy vs. lobectomy for early non-small-cell lung cancer: a nationwide database study in Japan

Open Access Lung Cancer Original Article

The role of segmentectomy has expanded to include resection of peripheral small-sized early non-small-cell lung cancer (NSCLC), as this technique may better preserve the lung function than lobectomy [ 1 , 2 ]. Recently, a Japanese randomized …

Post-radiotherapy stage III/IV non-small cell lung cancer radiomics research: a systematic review and comparison of CLEAR and RQS frameworks

Open Access Radiotherapy Chest

Lung cancer is the second most prevalent malignancy worldwide, with approximately 2.2 million newly diagnosed cases in 2020 [ 1 ], the majority of which are nonsmall cell lung cancer (NSCLC), comprising nearly 84% of cases [ 2 ]. NSCLC stage I and …